“Pipeline drug targets with human genetic evidence of disease association are twice as likely to lead to approval.”
(King et al. 2019)
EXPAND GENETIC DISCOVERY
AI and Machine Learning more quickly
and comprehensively identify
the molecular drivers of disease
STRATIFY CLINICAL TARGETS
Comprehensive Genomic Landscapes
guide biomarker selection for
clinical trial segregation criteria
ACCELERATE CDx DEVELOPMENT
Genetic Evidence identifies genomic biomarkers to double companion diagnostic submission success
Our curated Genomic Landscapes provide immediate insight into the genomic evidence for every phenotype, therapy, disease, gene, and variant.
Pharmaceutical and biotech companies license Genomenon’s comprehensive Genomic Landscapes to identify and prioritize genomic biomarkers for drug discovery, clinical trial candidate selection, and CDx submission.
With You Through the Development Process
Genomenon’s Curated Genomic Datasets help Pharma at all stages of drug development
Genomenon’s comprehensive and organized collection of genomic evidence significantly accelerated our work in several key steps along our development process.
Genomenon’s methodology improved the efficiency and completeness of our literature review process.